Updated with comment from Retractable Technologies
A 3-judge panel of the U.S. Court of Appeals for the 5th Circuit ruled Dec. 2 that RTI’s claim that BD violated a section of the Sherman Antitrust Act was “infirm as a matter of law.”
“First, patent infringement, which operates to increase competition, is not anticompetitive conduct. Second, false advertising is a slim, and here nonexistent, reed for a [Sherman Act] claim. Third, the allegation that BD ‘tainted’ the market for retractable syringes while surreptitiously plotting to offer its own retractable a few years later is unsupported and incoherent,” Judge Edith Jones wrote.
The 5th Circuit also upheld the false advertising claim and sent it back to the U.S. District Court for Eastern Texas, which will decide how much profit BD must disgorge.
The news sent RVP shares down -46.9% to a $1.30-per-share close Dec. 2. BDX shares closed up 0.6% at $165.53 apiece that day. Neither firm nor their lawyers responded to requests for comment.
The company responded by saying it is evaluating the appeals court’s rulings and conferring with legal counsel to consider possible future actions.
Retractable prez & CEO Thomas Shaw said the decision is “unfortunate for the American healthcare industry in that it will likely reinforce the inability of small medical products companies to gain access to healthcare markets that are important to the survival of emerging companies with new technologies that will save lives and offer lower prices to medical consumers and insurers.”
The case dates back to 2001, when Little Elm, Texas-based RTI sued BD for patent infringement, settling for $100 million in 2004. RTI sued again barely 3 years later, alleging patent infringement and anti-trust violations. The case was split, with the anti-trust portion on hold while the patent infringement claims were litigated. A federal appeals court decided in July 2011 to reverse an earlier jury finding that both the 1m and 3ml sizes of the BD syringe infringed the Retractable patent, ruling that only the smaller size trespassed on the intellectual property.
The anti-trust phase of the proceedings began in 2010; eventually BD was found to have advertised false claims that its Integra, Safety-Lok, SafetyGlide and Eclipse safety syringes boast the “world’s sharpest needle” and about the amount of “waste space” in RTI’s VanishPoint syringe. In September 2013 a jury found for RTI, awarding $113.5 million after finding that BD violated the Lanham Act’s false advertising proscription. Franklin Lakes, N.J.-based BD later lost an initial bid to toss the case, after the Easter Texas court ruled that infringement can constitute anti-competitive behavior. In October that court declined BD’s bid to overturn the verdict and ordered the company in January 2015 to pony up more than $352.2 million in damages, including more than $11.7 million in attorneys’ fees, plus pre- and post-judgment interest and costs.
Material from Reuters was used in this report.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.